EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment patterns and drug survival for generalized pustular psoriasis: A patient journey study using a Japanese claims database

Yayoi Tada, Jia Guan, Ryoko Iwasaki, Akimichi Morita iD

The Journal of Dermatology · 2024

DOI: 10.1111/1346-8138.17097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Yayoi Tada und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Teikyo University Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Etretinate, Psoriasis, Biological Products, Cyclosporins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nippon Boehringer Ingelheim Co., Ltd., Boehringer Ingelheim Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Generalized pustular psoriasis (GPP) is a potentially life‐threatening skin disease. Although several medications are approved for treating GPP in Japan, there are limited data on real‐world treatment patterns or drug survival (the number of prescribed days of treatment). This retrospective cohort study describes drug survival and treatment patterns of patients with newly diagnosed GPP (International Classification of Diseases, 10th Revision code L40.1), and ≥1 year of follow‐up, using de‐identified claims data (Medical Data Vision Co., Ltd.) from January 2016 to August 2021. Most (97.0%) of the 434 Japanese patients received first‐line therapy of etretinate (26.4%), topical medications (14.7%), or cyclosporin (14.3%); 80.0% and 60.1% of patients received a second and third line of therapy (LOT), respectively. Use of etretinate (12.6%) and cyclosporin (5.9%) decreased in second‐line therapies, whereas use of biologics (interleukin [IL]‐17, 14.3%; IL‐23 inhibitors, 7.6%) and topical medications (22.1%) increased or remained consistent. Approximately 50% of biologics were prescribed in combination with systemic medications or systemic corticosteroids. Median (range) time to next therapy (TTNT) was 2.8 (0.03–48.07) months for first‐line therapy and 3.3 (0.03–52.97) months for all other LOTs. TTNT was longer for combination therapies (up to 16.5 months) compared with monotherapies (up to 7.5 months). Biologics exhibited longer drug survival with fewer treatment episodes compared with non‐biologic systemic medications. Among frequently used therapies, the median (95% confidence interval) drug survival was 8.8 (5.8–11.8) months for etretinate, 4.3 (2.2–6.9) months for systemic corticosteroids, and 19.6 (16.1–26.7) months for secukinumab. Treatment patterns varied considerably, highlighting the need for treatment algorithms and effective, well‐tolerated medications to support patients to help them remain on long‐term therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EtretinatePsoriasisBiological ProductsCyclosporinsHumansJapanRetrospective StudiesAdrenal Cortex Hormones

Stichwörter der Autor:innen

Japangeneralized pustular psoriasisrare diseasesskin diseasestherapeutics

Substanzen

EtretinateBiological ProductsAdrenal Cortex HormonesCyclosporins

Autor:innen und Institutionen

  • Department of Dermatology, Teikyo University Hospital, Tokyo, Japan.
  • Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
  • Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan.
  • Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

ORCID-Profile: Akimichi Morita

Förderung

  • Nippon Boehringer Ingelheim Co., Ltd.
  • Boehringer Ingelheim Japan

Zitieren

APA

Tada, Y., Guan, J., Iwasaki, R., & Morita, A. (2024). Treatment patterns and drug survival for generalized pustular psoriasis: A patient journey study using a Japanese claims database. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17097

Vancouver

Tada Y, Guan J, Iwasaki R, Morita A. Treatment patterns and drug survival for generalized pustular psoriasis: A patient journey study using a Japanese claims database. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17097

BibTeX
@article{Tada2024,
  author = {Tada, Yayoi and Guan, Jia and Iwasaki, Ryoko and Morita, Akimichi},
  title = {Treatment patterns and drug survival for generalized pustular psoriasis: A patient journey study using a Japanese claims database},
  journal = {The Journal of Dermatology},
  year = {2024},
  doi = {10.1111/1346-8138.17097}
}
Kostenlos starten →